左乙酰亮氨酸用于治疗C型尼曼-匹克病的神经系统表现。
完整摘要 · 中文译文
引言:C型尼曼-匹克病(NPC)是一种罕见的、进行性神经退行性溶酶体贮积病,其疾病特异性治疗选择仍然有限。直到最近,标准治疗药物米格鲁司他仍是唯一获批的可减缓疾病进展的疗法,但对于其他耐受性良好、可口服、可穿透中枢神经系统的治疗药物仍存在大量未满足的需求。 涵盖领域:本评估综述了左乙酰亮氨酸的化学、药理学、药代动力学、临床疗效、安全性和监管状态,该药是一种口服修饰氨基酸,于2024-2026年获批用于NPC的神经系统表现。证据来源于2期评分者盲法试验(IB1001-201)、关键性3期(IB1001-301)随机安慰剂对照交叉试验及其长期开放标签扩展期。对PubMed、ClinicalTrials.gov和监管数据库进行了截至2026年7月的结构化检索。 专家意见:左乙酰亮氨酸在6-12周内产生快速的症状性获益,并在≥36个月内表现出疾病修饰作用,具有口服给药途径和良好的安全性特征。这些特性使其区别于现有疗法,并使其成为NPC的基础性治疗。
完整摘要 · 英文原文
INTRODUCTION: Niemann-Pick disease type C (NPC) is a rare, progressive, neurodegenerative lysosomal disorder for which disease-specific treatment options remain limited. Until recently, the standard of care drug miglustat was the only approved therapy that slows disease progression but there is a substantial unmet need for additional well-tolerated, orally available, central nervous system penetrant therapies. AREAS COVERED: This evaluation reviews the chemistry, pharmacology, pharmacokinetics, clinical efficacy, safety, and regulatory status of levacetylleucine, an oral modified amino acid approved in 2024-2026 for the neurological manifestations of NPC. Evidence is drawn from Phase 2, rater-blinded trial (IB1001-201), the pivotal, Phase 3 (IB1001-301), randomized, placebo-controlled crossover trial, and its long-term open-label Extension Phase. A structured search of PubMed, ClinicalTrials.gov, and regulatory databases through July 2026 was undertaken. EXPERT OPINION: Levacetylleucine produces a rapid, symptomatic benefit within 6-12 weeks and exhibits disease-modifying effects over ≥ 36 months, with an oral route of administration, and a benign safety profile. These attributes distinguish it from existing therapies and position it as a foundational treatment for NPC.